Nabriva Therapeutics Plc's ROA from the second quarter of 2023 to the second quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nabriva Therapeutics Plc's ROA in the second quarter of 2023?
Nabriva Therapeutics Plc recorded a cumulative net loss of $-55 million during 12 months ending in the second quarter of 2023, resulting in a negative return on assets (ROA) of -98.79%.

However, within the Healthcare sector 1051 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2023 quarter, so far to 5264, from total ROA ranking in the first quarter of 2023 at 5296.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter
Y / Y Total Assets Change	-73.85 %	-52.42 %	-23.53 %	-57.27 %	-53.06 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-55	-54	-57	-47	-47
Return On Assets (TTM)	-98.79 %	-85.55 %	-81.81 %	-57.95 %	-50.34 %
NBRV's Total Ranking	# 5264	# 5296	# 6011	# 5131	# 5175
Total Assets (TTM) in million	11	24	156	32	40
Seq. Total Assets Change	-56.54 %	-84.42 %	391.06 %	-21.38 %	-20.9 %
Seq. Net Income Change	-	-	-	-	-

NBRV's 5 Years Annual ROA >> Back to NBRV Management Effectiveness >> Compare NBRV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 509
Sector	# 1052
Overall	# 5157

Return On Assets Statistics
High	Average	Low
-57.11 %	-96.49 %	-191.62 %
(Mar 31 2022)		(Jun 30 2023)

Financial Statements
Nabriva Therapeutics Plc's Assets	$ 11 million	NBRV's Balance sheet
Nabriva Therapeutics Plc's Income	$ -12 million	Quarterly NBRV's Income Statement
NBRV's Income by Division		See NBRV's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018
Y / Y Total Assets Change	-23.53 %	14.68 %	-10.63 %	-6.76 %	24.04 %
Total Assets in million	156	204	178	199	214
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-57	-49	-69	-83	-115
Annual Return On Assets	-36.61 %	-24.21 %	-39.01 %	-41.52 %	-53.7 %

NBRV's 5 Years Annual ROA >> Back to NBRV Management Effectiveness >> Compare NBRV ROA to its Competitors

More Return On Assets Ratios
NBRV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NBRV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NBRV's Competitors
Subscribers only: Roa for Nabriva Therapeutics Plc's Suppliers
Subscribers only: Return On Assets for NBRV's Customers

You may also want to know
NBRV's Roi	NBRV's Inventory Turnover Ratio	NBRV's Growth Rates	NBRV's Dividend Comparisons
	NBRV's Profitability Ratios	NBRV's Asset Turnover Ratio	NBRV's Dividend Growth
NBRV's Roe	NBRV's Valuation Ratios	NBRV's Financial Strength Ratios	NBRV's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2023, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.